CA2353775A1 - Compositions et methodes de traitement d'une tumeur - Google Patents

Compositions et methodes de traitement d'une tumeur Download PDF

Info

Publication number
CA2353775A1
CA2353775A1 CA002353775A CA2353775A CA2353775A1 CA 2353775 A1 CA2353775 A1 CA 2353775A1 CA 002353775 A CA002353775 A CA 002353775A CA 2353775 A CA2353775 A CA 2353775A CA 2353775 A1 CA2353775 A1 CA 2353775A1
Authority
CA
Canada
Prior art keywords
seq
polypeptide
antibody
acid sequence
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002353775A
Other languages
English (en)
Inventor
David Botstein
Audrey Goddard
Austin L. Gurney
Kenneth Hillan
David A. Lawrence
Margaret Ann Roy
William I. Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1999/005028 external-priority patent/WO1999046281A2/fr
Priority claimed from PCT/US1999/012252 external-priority patent/WO1999063088A2/fr
Priority claimed from PCT/US1999/020111 external-priority patent/WO2000012708A2/fr
Priority claimed from PCT/US1999/021090 external-priority patent/WO2000015796A2/fr
Priority claimed from PCT/US1999/028409 external-priority patent/WO2000032778A2/fr
Priority claimed from PCT/US1999/028313 external-priority patent/WO2000032221A2/fr
Priority claimed from PCT/US1999/028301 external-priority patent/WO2000032776A2/fr
Priority claimed from PCT/US1999/028565 external-priority patent/WO2000037638A2/fr
Application filed by Individual filed Critical Individual
Publication of CA2353775A1 publication Critical patent/CA2353775A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne des compositions et des methodes de diagnostic et de traitement d'une croissance ou d'une prolifération cellulaire néoplastique chez un mammifère, notamment chez l'humain. L'invention est fondée sur l'identification de gènes amplifiés dans le génome de cellules tumorales. Cette amplification génique est censée s'accompagner de la surexpression du produit génique par comparaison avec des cellules normales provenant du même type de tissu, et contribue à l'action cancérigène. En conséquence, les protéines codées par les gènes amplifiés sont réputées être des cibles utiles pour le diagnostic et/ou le traitement (y compris la prévention) de certains cancers, et peuvent agir comme prédicteurs du pronostic d'un traitement anticancéreux. L'invention concerne également de nouveaux polypeptides et des molécules d'acide nucléique codant ces polypeptides. Elle concerne en outre des vecteurs et des cellules hôtes comprenant lesdites séquences d'acide nucléique, des molécules polypeptidiques chimères comprenant les polypeptides fusionnés à des séquences polypeptidiques hétérologues, des anticorps se liant aux polypeptides, et des méthodes de production des polypeptides de l'invention.
CA002353775A 1998-12-22 1999-12-16 Compositions et methodes de traitement d'une tumeur Abandoned CA2353775A1 (fr)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US11329698P 1998-12-22 1998-12-22
US60/113,296 1998-12-22
PCT/US1999/005028 WO1999046281A2 (fr) 1998-03-10 1999-03-08 Nouveaux polypeptides et acides nucleiques les codant
USPCT/US99/05028 1999-03-08
USPCT/US99/12252 1999-06-02
PCT/US1999/012252 WO1999063088A2 (fr) 1998-06-02 1999-06-02 Proteines membranaires et acides nucleiques codant ces proteines
USPCT/US99/20111 1999-09-01
PCT/US1999/020111 WO2000012708A2 (fr) 1998-09-01 1999-09-01 Nouveaux pro-polypeptides et sequences correspondantes
PCT/US1999/021090 WO2000015796A2 (fr) 1998-09-16 1999-09-15 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
USPCT/US99/21090 1999-09-15
USPCT/US99/28409 1999-11-30
PCT/US1999/028409 WO2000032778A2 (fr) 1998-12-01 1999-11-30 Methodes et compositions permettant d'inhiber la croissance de cellules neoplasiques
USPCT/US99/28313 1999-11-30
PCT/US1999/028313 WO2000032221A2 (fr) 1998-12-01 1999-11-30 Promotion et inhibition de l'angiogenese et de la vascularisation cardiaque
PCT/US1999/028301 WO2000032776A2 (fr) 1998-12-01 1999-12-01 Polypeptides secretes et transmembranaires et acides nucleiques les codant
USPCT/US99/28301 1999-12-01
USPCT/US99/28565 1999-12-02
PCT/US1999/028565 WO2000037638A2 (fr) 1998-12-22 1999-12-02 Methodes permettant d'inhiber la croissance de cellules neoplasiques
PCT/US1999/030095 WO2000037640A2 (fr) 1998-12-22 1999-12-16 Compositions et methodes de traitement d'une tumeur

Publications (1)

Publication Number Publication Date
CA2353775A1 true CA2353775A1 (fr) 2000-06-29

Family

ID=22348649

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002353775A Abandoned CA2353775A1 (fr) 1998-12-22 1999-12-16 Compositions et methodes de traitement d'une tumeur

Country Status (9)

Country Link
EP (1) EP1141289A2 (fr)
JP (1) JP2003524390A (fr)
KR (1) KR20010102960A (fr)
AU (1) AU2192800A (fr)
CA (1) CA2353775A1 (fr)
IL (1) IL143212A0 (fr)
MX (1) MXPA01006345A (fr)
WO (1) WO2000037640A2 (fr)
ZA (2) ZA200103885B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217788B2 (en) 1996-03-14 2007-05-15 Human Genome Sciences, Inc. Human tumor necrosis factor delta polypeptides
US6541224B2 (en) 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
DE69834334T2 (de) 1997-08-26 2007-04-26 Zymogenetics, Inc., Seattle Für adipozyten spezifische protein homologe
US20020192752A1 (en) 1998-09-09 2002-12-19 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US7282562B2 (en) 1999-08-31 2007-10-16 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
JP3988821B2 (ja) * 1999-08-31 2007-10-10 ジェネンテック・インコーポレーテッド 免疫関連疾患を治療するための組成物及び方法
ES2444710T3 (es) * 2000-06-22 2014-02-26 Amgen, Inc. Uso de un anticuerpo específico para un polipéptido similar a IL-17
EP1401870A4 (fr) 2001-05-24 2006-04-19 Human Genome Sciences Anticorps contre le facteur de necrose tumorale delta (april)
JP2006512903A (ja) * 2002-09-11 2006-04-20 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための新規組成物と方法
EP1831370A4 (fr) 2004-12-13 2009-08-12 Alethia Biotherapeutics Inc Sequences polynucleotidiques et polypeptidiques participant au remodelage osseux
WO2007140907A1 (fr) * 2006-06-07 2007-12-13 Bayer Healthcare Ag Utilisation de sérine endopeptidase 22 (prss22) en tant que cible thérapeutique ou diagnostique

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411860A (en) * 1992-04-07 1995-05-02 The Johns Hopkins University Amplification of human MDM2 gene in human tumors
EP0654092B1 (fr) * 1992-06-26 2003-09-10 The Trustees Of Princeton University Procede de detection de cellules precancereuses ou cancereuses au moyen d'anticorps ou de sondes de p90 et de p53
AU2212299A (en) * 1998-01-05 1999-07-26 Genentech Inc. Compositions and methods for the treatment of tumor

Also Published As

Publication number Publication date
ZA200104218B (en) 2002-05-23
WO2000037640A3 (fr) 2000-12-28
AU2192800A (en) 2000-07-12
IL143212A0 (en) 2002-04-21
ZA200103885B (en) 2002-05-14
EP1141289A2 (fr) 2001-10-10
WO2000037640A2 (fr) 2000-06-29
MXPA01006345A (es) 2002-07-02
WO2000037640A9 (fr) 2000-11-02
KR20010102960A (ko) 2001-11-17
JP2003524390A (ja) 2003-08-19

Similar Documents

Publication Publication Date Title
AU2003200731C1 (en) Compositions and methods for the treatment of tumor
US20050176104A1 (en) Compositions and methods for the treatment of tumor
EP1657256B1 (fr) Compositions et méthodes pour traitement des tumeurs
AU776600B2 (en) Compositions and methods for the treatment of tumors
EP1642907B1 (fr) Composition et procédés de diagnostic de tumeurs
CA2353775A1 (fr) Compositions et methodes de traitement d'une tumeur
WO2001005836A1 (fr) Compositions polypeptidiques et methodes de traitement des tumeurs
AU756400B2 (en) Compositions and methods for the treatment of tumor
AU2003200721B2 (en) Compositions and methods for the treatment of tumor
CA2478730A1 (fr) Compositions et procedes pour le traitement de tumeurs
WO2000053754A1 (fr) Compositions et methodes pour le traitement de tumeurs
NZ513423A (en) Compositions and methods for the treatment of tumors
ZA200106595B (en) Compositions and methods for the treatment of tumor.

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued